These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

691 related items for PubMed ID: 19686365

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.
    Lowe NJ, Lask G, Yamauchi P, Moore D.
    J Am Acad Dermatol; 2002 Dec; 47(6):834-40. PubMed ID: 12451366
    [Abstract] [Full Text] [Related]

  • 3. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet.
    Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N, Botox Facial Aesthetics Study Team.
    Dermatol Surg; 2005 Mar; 31(3):257-62. PubMed ID: 15841623
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
    Monheit G, Carruthers A, Brandt F, Rand R.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
    Cheon HI, Jung N, Won CH, Kim BJ, Lee YW.
    Dermatol Surg; 2019 Dec; 45(12):1610-1619. PubMed ID: 30893169
    [Abstract] [Full Text] [Related]

  • 6. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study.
    Prager W, Wissmüller E, Kollhorst B, Williams S, Zschocke I.
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2155-60. PubMed ID: 21134046
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
    Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J.
    J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
    [Abstract] [Full Text] [Related]

  • 8. Botulinum toxin A: a 9-month clinical and 3D in vivo profilometric crow's feet wrinkle formation study.
    Levy JL, Servant JJ, Jouve E.
    J Cosmet Laser Ther; 2004 May; 6(1):16-20. PubMed ID: 15370408
    [Abstract] [Full Text] [Related]

  • 9. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines.
    Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J.
    J Am Acad Dermatol; 2004 Aug; 51(2):223-33. PubMed ID: 15280841
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
    Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W.
    Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
    [Abstract] [Full Text] [Related]

  • 11. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
    Farahvash MR, Arad S.
    J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
    [Abstract] [Full Text] [Related]

  • 12. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J, Rivkin A, Donofrio L, Bertucci V, Somogyi C, Lei X, Davis PG, Campo A, Beddingfield FC.
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group.
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [Abstract] [Full Text] [Related]

  • 14. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.
    Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S2-9. PubMed ID: 17241410
    [Abstract] [Full Text] [Related]

  • 15. Reproducibility of two four-point clinical severity scores for lateral canthal lines (crow's feet).
    Hund T, Ascher B, Rzany B, SMILE STUDY GROUP.
    Dermatol Surg; 2006 Oct; 32(10):1256-60. PubMed ID: 17034375
    [Abstract] [Full Text] [Related]

  • 16. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women.
    Phillips TJ, Symons J, Menon S, HT Study Group.
    J Am Acad Dermatol; 2008 Sep; 59(3):397-404.e3. PubMed ID: 18625536
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
    Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport myofascial pain study group.
    Pain; 2006 Nov; 125(1-2):82-8. PubMed ID: 16750294
    [Abstract] [Full Text] [Related]

  • 18. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.
    Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C.
    Neurol Sci; 2005 Apr; 26(1):26-31. PubMed ID: 15877184
    [Abstract] [Full Text] [Related]

  • 19. [Botulinum: fashionable drug and effective medication. What the "miracle weapon against crow's feet" can do in addition].
    Stiefelhagen P.
    MMW Fortschr Med; 2003 Apr 03; 145(14):4-6. PubMed ID: 15072266
    [No Abstract] [Full Text] [Related]

  • 20. A Prospective, Neurophysiologic Comparative Study to Assess the Efficacy and Duration of Effect of IncobotulinumtoxinA and AbobotulinumtoxinA in the Treatment of Crow's Feet.
    Saybel A, Artemenko A, Nikitin S, Kurenkov A.
    J Drugs Dermatol; 2015 Nov 03; 14(11):1291-6. PubMed ID: 26580879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.